ConductScience.org, home

Paper36906275

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.

Hines MR and 30 others. Transplant Cell Ther, 2023. Cited by 338 papers, by iCite.

Cite this record

ConductScience Library. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Papers, record 36906275. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36906275

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
PubMed
Journal
Transplant Cell Ther
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
338
iCite
Relative citation ratio, by iCite
30.5
iCite
Revised in PubMed
2025-10-09
PubMed

Authors31

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hines MRMelissa R
2Knight TETristan E
3McNerney KOKevin O
4Leick MBMark B
5Jain TTania
6Ahmed SSairah
7Frigault MJMatthew J
8Hill JAJoshua A
9Jain MDMichael D
10Johnson WTWilliam T
11Lin YYi
12Mahadeo KMKris M
13Maron GMGabriela M
14Marsh RARebecca A
15Neelapu SSSattva S
16Nikiforow SSarah
17Ombrello AKAmanda K
18Shah NNNirav N
19Talleur ACAimee C
20Turicek DDavid

Source PubMed

See all 31 authorsDownload CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lymphohistiocytosis, HemophagocyticMajor topic
Neurotoxicity SyndromesMajor topic
Adult
Humans
United States
Child
T-Lymphocytes
Immunotherapy, Adoptive
Cytokine Release Syndrome

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
P50 CA186781NCI NIH HHSUnited StatesP50CA186781PubMedNIH RePORTER
ZIA BC011823Intramural NIH HHSUnited StatesZIABC011823PubMed and NIHNIH RePORTER

Download CSV of grants

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT06072989Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid TumorsBackgroundClinicalTrials.gov
NCT06703216Pre-emptive Anakinra for Cytokine Event ReductionBackgroundClinicalTrials.gov
NCT06879340Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell MalignanciesBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in41067707Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].https://conductscience.org/library/papers/41067707

Source PubMed

Download CSV of comments and corrections

References140

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130965140Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/30965140PubMed
230753567CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.J Natl Cancer Inst2019https://conductscience.org/library/papers/30753567PubMed
335708727HLH treatment: smarter, not harder.Blood2022https://conductscience.org/library/papers/35708727PubMed
429434334Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/29434334PubMed
529385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
635986653Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy.Transfusion2022https://conductscience.org/library/papers/35986653PubMed
736316312Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma.Blood Cancer J2022https://conductscience.org/library/papers/36316312PubMed
832374962Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.N Engl J Med2020https://conductscience.org/library/papers/32374962PubMed
936131317Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study.Orphanet J Rare Dis2022https://conductscience.org/library/papers/36131317PubMed
1024876563Current concepts in the diagnosis and management of cytokine release syndrome.Blood2014https://conductscience.org/library/papers/24876563PubMed
1135266965Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.JAMA Oncol2022https://conductscience.org/library/papers/35266965PubMed
1231515353Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis.Haematologica2020https://conductscience.org/library/papers/31515353PubMed
1334114322Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill children.Pediatr Blood Cancer2021https://conductscience.org/library/papers/34114322PubMed
1427632680Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.Crit Care Med2017https://conductscience.org/library/papers/27632680PubMed
1523778995Recombinant human thrombopoietin is an effective treatment for thrombocytopenia in hemophagocytic lymphohistiocytosis.Ann Hematol2013https://conductscience.org/library/papers/23778995PubMed
1633496754Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.Blood Adv2021https://conductscience.org/library/papers/33496754PubMed
1724553386Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci Transl Med2014https://conductscience.org/library/papers/24553386PubMed
1821830940Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N Engl J Med2011https://conductscience.org/library/papers/21830940PubMed
1931912207Transfusion strategies in non-bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine.Intensive Care Med2020https://conductscience.org/library/papers/31912207PubMed
2034309174Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia.Pediatr Blood Cancer2021https://conductscience.org/library/papers/34309174PubMed

See all 140 referencesDownload CSV of references

Cited by238

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 338 citations.

PMIDTitleJournalYearIn PapersSource
42964569Artificial intelligence-enabled nursing surveillance for pediatric cancer immunotherapy: integrating biomarkers, patient-reported outcomes, and long-term toxicity management.Front Med (Lausanne)2026https://conductscience.org/library/papers/42964569PubMed
42939519Emapalumab in IFN-γ-Driven Hyperinflammatory Disorders: Mechanisms, Clinical Evidence, and Emerging Therapeutic Applications.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42939519PubMed
42936537Chimeric antigen receptor-engineered cell therapy for asthma: advances in targeting type 2 inflammation and translational challenges.Front Immunol2026https://conductscience.org/library/papers/42936537PubMed
42935367An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres.Med J Aust2026https://conductscience.org/library/papers/42935367PubMed
42921052When, Where, and How Much: Toward Smarter Design and Delivery of CAR T‑Cell Therapy.ACS Bio Med Chem Au2026https://conductscience.org/library/papers/42921052PubMed
42890994Chimeric Antigen Receptor T-cell (CAR-T) Therapy in Autoimmune Diseases: A Narrative Review.Cureus2026https://conductscience.org/library/papers/42890994PubMed
42890889Immune-effector and infection-associated reporting patterns of CD20×CD3 bispecific antibodies in B-cell lymphoma: a label-anchored FAERS analysis with descriptive JADER contextualization.Front Immunol2026https://conductscience.org/library/papers/42890889PubMed
42866565Precision Management of Tumor-Associated Fever: From Classification to Targeted Intervention.Cancer Manag Res2026https://conductscience.org/library/papers/42866565PubMed
42819351CAR T cell cancer immunotherapy: who does the job?Front Immunol2026https://conductscience.org/library/papers/42819351PubMed
42809697CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma.Cancer J2026https://conductscience.org/library/papers/42809697PubMed
42807139Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis in the Gulf Cooperation Council: a modified Delphi approach.Front Immunol2026https://conductscience.org/library/papers/42807139PubMed
42769528The transformative potential of lipid nanoparticles tailored for acute myeloid leukemia immunotherapy.Front Immunol2026https://conductscience.org/library/papers/42769528PubMed
42767771Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.J Immunother Cancer2026https://conductscience.org/library/papers/42767771PubMed
42739214Beyond the Storm: CXCL9 and the New Era of Precision Hemophagocytic Lymphohistiocytosis Diagnostics.Diagnostics (Basel)2026https://conductscience.org/library/papers/42739214PubMed
42714733CRS and ICANS: Early detection and personalized management.Blood Res2026https://conductscience.org/library/papers/42714733PubMed
42706167[Mechanism and clinical progress of JAK inhibitors in hemophagocytic lymphohistiocytosis].Zhonghua Xue Ye Xue Za Zhi2026https://conductscience.org/library/papers/42706167PubMed
42650392Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study.Children (Basel)2026https://conductscience.org/library/papers/42650392PubMed
42602092Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature.Front Immunol2026https://conductscience.org/library/papers/42602092PubMed
42578568Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and Opportunities.Blood Cancer Discov2026https://conductscience.org/library/papers/42578568PubMed
42489798Incorporating Immunotherapies into the Evolving Standard of Care for Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.Paediatr Drugs2026https://conductscience.org/library/papers/42489798PubMed

See all 238 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36906275

GET https://conductscience.org/api/papers/v1/36906275/authors?page=2